The additive effect of periodontitis with hypertension on risk of systemic disease and mortality.


Journal

Journal of periodontology
ISSN: 1943-3670
Titre abrégé: J Periodontol
Pays: United States
ID NLM: 8000345

Informations de publication

Date de publication:
07 2022
Historique:
revised: 24 01 2022
received: 29 10 2021
accepted: 10 04 2022
pubmed: 24 4 2022
medline: 29 7 2022
entrez: 23 4 2022
Statut: ppublish

Résumé

Recent evidence suggests that periodontitis (PD) causes hypertension, which is a precursor to development of other systemic diseases. The aim of this study was to examine the effect of hypertension and PD on the risk of subsequent systemic disease. This longitudinal cohort study included 244,393 UK Biobank participants who were free of systemic disease other than hypertension at baseline. Self-reported responses of painful gums or loose teeth were surrogates for PD. Hypertensives were identified by clinical diagnosis, or elevated blood pressure (≥140/90 mmHg). Systemic diseases including cancer, cardiovascular disease (CVD), and diabetes were identified from linked diagnostic codes. Multivariable Cox proportional hazard models were used to quantify the risk of systemic diseases and all-cause mortality, stratified by hypertensive and PD status. The average age of the study population was 55.4 years (standard deviation [SD:] 8.1 years), and 130,220 (53.3%) participants were female. At baseline, 131,566 (53.8%) participants were hypertensive and 4.5% reported PD. The incidence rates of all systemic diseases were higher in hypertensive than non-hypertensive participants of the same PD status. In hypertensives, an additive effect was observed for PD on the risks of CVD (adjusted hazard ratio [HR]: 1.35, 95% confidence interval [CI]: 1.21-1.53) and respiratory disease (HR: 1.11, 95% CI: 0.95-1.30) compared to hypertensive healthy controls. Hypertensives with PD have exacerbated risks of several systemic diseases. Future interventional studies should consider the effect of periodontal treatment on systemic outcomes in targeted hypertensive populations.

Sections du résumé

BACKGROUND
Recent evidence suggests that periodontitis (PD) causes hypertension, which is a precursor to development of other systemic diseases. The aim of this study was to examine the effect of hypertension and PD on the risk of subsequent systemic disease.
METHODS
This longitudinal cohort study included 244,393 UK Biobank participants who were free of systemic disease other than hypertension at baseline. Self-reported responses of painful gums or loose teeth were surrogates for PD. Hypertensives were identified by clinical diagnosis, or elevated blood pressure (≥140/90 mmHg). Systemic diseases including cancer, cardiovascular disease (CVD), and diabetes were identified from linked diagnostic codes. Multivariable Cox proportional hazard models were used to quantify the risk of systemic diseases and all-cause mortality, stratified by hypertensive and PD status.
RESULTS
The average age of the study population was 55.4 years (standard deviation [SD:] 8.1 years), and 130,220 (53.3%) participants were female. At baseline, 131,566 (53.8%) participants were hypertensive and 4.5% reported PD. The incidence rates of all systemic diseases were higher in hypertensive than non-hypertensive participants of the same PD status. In hypertensives, an additive effect was observed for PD on the risks of CVD (adjusted hazard ratio [HR]: 1.35, 95% confidence interval [CI]: 1.21-1.53) and respiratory disease (HR: 1.11, 95% CI: 0.95-1.30) compared to hypertensive healthy controls.
CONCLUSIONS
Hypertensives with PD have exacerbated risks of several systemic diseases. Future interventional studies should consider the effect of periodontal treatment on systemic outcomes in targeted hypertensive populations.

Identifiants

pubmed: 35460076
doi: 10.1002/JPER.21-0621
pmc: PMC9544472
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1024-1035

Subventions

Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom

Informations de copyright

© 2022 The Authors. Journal of Periodontology published by Wiley Periodicals LLC on behalf of American Academy of Periodontology.

Références

J Clin Periodontol. 2021 Sep;48(9):1260-1269
pubmed: 34109647
J Dent Res. 2014 Nov;93(11):1045-53
pubmed: 25261053
Int J Environ Res Public Health. 2021 Jan 02;18(1):
pubmed: 33401662
Periodontol 2000. 2020 Feb;82(1):257-267
pubmed: 31850640
Endocr Metab Immune Disord Drug Targets. 2016;16(1):12-20
pubmed: 26739959
Hypertension. 2018 Dec;72(6):1365-1373
pubmed: 30540406
J Dent Res. 2021 Oct;100(11):1228-1235
pubmed: 34271846
Clin Exp Dent Res. 2021 Feb;7(1):109-122
pubmed: 33124761
Crit Rev Oral Biol Med. 2000;11(3):356-65
pubmed: 11021635
Eur Heart J. 2019 Nov 1;40(42):3459-3470
pubmed: 31504461
Lancet. 2012 Jul 7;380(9836):37-43
pubmed: 22579043
J Clin Periodontol. 2013 Apr;40 Suppl 14:S135-52
pubmed: 23627324
J Clin Periodontol. 2021 Feb;48(2):180-204
pubmed: 33103263
J Periodontol. 2016 Dec;87(12):1474-1483
pubmed: 27523519
J Intern Med. 2021 Apr;289(4):532-546
pubmed: 32969093
J Clin Periodontol. 2008 Sep;35(9):741-7
pubmed: 18647204
United European Gastroenterol J. 2019 Nov;7(9):1241-1249
pubmed: 31700637
Am Heart J. 2006 Jan;151(1):47
pubmed: 16368290
Hypertension. 2021 May 5;77(5):1765-1774
pubmed: 33775115
J Clin Periodontol. 2017 Mar;44(3):266-274
pubmed: 28036104
Cardiovasc Res. 2020 Jan 1;116(1):28-39
pubmed: 31549149
J Clin Periodontol. 2021 Dec;48(12):1587-1596
pubmed: 34409647
Front Med (Lausanne). 2020 Nov 23;7:604980
pubmed: 33330570
J Clin Periodontol. 2020 Feb;47(2):160-172
pubmed: 31680283
Int J Epidemiol. 2012 Dec;41(6):1625-38
pubmed: 23220717
Int J Immunopathol Pharmacol. 2018 Jan-Dec;32:394632017751786
pubmed: 29363361
JAMA Intern Med. 2016 Apr;176(4):524-32
pubmed: 26975032
J Am Heart Assoc. 2017 Mar 29;6(4):
pubmed: 28356279
J Clin Periodontol. 2013 Apr;40 Suppl 14:S8-19
pubmed: 23627336
J Periodontol. 2022 Jul;93(7):1024-1035
pubmed: 35460076

Auteurs

Harriet Larvin (H)

School of Dentistry, University of Leeds, Leeds, UK.

Jing Kang (J)

Oral Biology, School of Dentistry, University of Leeds, Leeds, UK.

Vishal R Aggarwal (VR)

School of Dentistry, University of Leeds, Leeds, UK.

Sue Pavitt (S)

School of Dentistry, University of Leeds, Leeds, UK.

Jianhua Wu (J)

School of Dentistry, University of Leeds, Leeds, UK.
Leeds Institute for Data Analytics, University of Leeds, Leeds, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH